LAP-话题@MedSci

#LAP#

37篇内容 | 1668人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1734659, encodeId=285e1e34659ec, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=卵巢癌新药olaparib获3期临床突破, objectType=article, longId=92108, objectId=5ff2921087a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ff2921087a, replyNumber=0, likeNumber=73, createdTime=2017-05-01, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ff2921087a, moduleTitle=卵巢癌新药olaparib获3期临床突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ff2921087a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734660, encodeId=eaee1e346606f, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=Neurology：ELAPSS评分可以预测未破裂颅内动脉瘤生长风险吗？, objectType=article, longId=94404, objectId=8e169440445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e169440445, replyNumber=0, likeNumber=65, createdTime=2017-10-10, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e169440445, moduleTitle=Neurology：ELAPSS评分可以预测未破裂颅内动脉瘤生长风险吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e169440445)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734665, encodeId=bb981e346650e, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=J Periodontol：非手术治疗可以有效减少LAP中Aa的JP2克隆表型, objectType=article, longId=111066, objectId=7e80111066d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e80111066d7, replyNumber=0, likeNumber=100, createdTime=2018-01-06, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e80111066d7, moduleTitle=J Periodontol：非手术治疗可以有效减少LAP中Aa的JP2克隆表型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e80111066d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734663, encodeId=c5b51e34663cd, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望, objectType=article, longId=108450, objectId=b39c1084500d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b39c1084500d, replyNumber=0, likeNumber=79, createdTime=2017-10-15, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b39c1084500d, moduleTitle=NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b39c1084500d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734661, encodeId=94c21e34661d1, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=J Endod：GuttaFlow Bioseal, GuttaFlow2, MTA Fillapex和AH Plus对人牙周膜干细胞的毒性研究, objectType=article, longId=95106, objectId=33df9510610, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33df9510610, replyNumber=0, likeNumber=68, createdTime=2017-06-12, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33df9510610, moduleTitle=J Endod：GuttaFlow Bioseal, GuttaFlow2, MTA Fillapex和AH Plus对人牙周膜干细胞的毒性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33df9510610)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734662, encodeId=10e51e346629e, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=Hepatology：DAA治疗失败的基因1 型丙型肝炎患者中，Sofosbuvir-velpatasvir-voxilaprevir使用效果评估, objectType=article, longId=100420, objectId=5e0f100420cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e0f100420cd, replyNumber=0, likeNumber=95, createdTime=2018-01-06, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e0f100420cd, moduleTitle=Hepatology：DAA治疗失败的基因1 型丙型肝炎患者中，Sofosbuvir-velpatasvir-voxilaprevir使用效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e0f100420cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734657, encodeId=727c1e34657d3, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=【ASCO 2016】预告：奥拉帕利（Olaparib）和BRCA突变相关研究, objectType=article, longId=69354, objectId=61d4693540e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61d4693540e, replyNumber=0, likeNumber=65, createdTime=2016-09-23, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61d4693540e, moduleTitle=【ASCO 2016】预告：奥拉帕利（Olaparib）和BRCA突变相关研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61d4693540e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734658, encodeId=18111e34658a9, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=ASCO 2016：奥拉帕利（Olaparib）全面开战：卵巢癌、乳腺癌、胃癌, objectType=article, longId=70433, objectId=5298e043346, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5298e043346, replyNumber=0, likeNumber=83, createdTime=2016-10-02, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5298e043346, moduleTitle=ASCO 2016：奥拉帕利（Olaparib）全面开战：卵巢癌、乳腺癌、胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5298e043346)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734656, encodeId=28931e3465668, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=lapatinib以及trastuzumab组合可以11天内消灭特定乳腺癌, objectType=article, longId=64864, objectId=a5bf6486466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5bf6486466, replyNumber=0, likeNumber=65, createdTime=2016-06-06, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5bf6486466, moduleTitle=lapatinib以及trastuzumab组合可以11天内消灭特定乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5bf6486466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734655, encodeId=bf4b1e346556a, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=医患沟通：细节出真知——解读LAP评估法中的有效沟通技巧, objectType=article, longId=51259, objectId=0f0951259e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0951259e7, replyNumber=0, likeNumber=76, createdTime=2015-11-04, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0951259e7, moduleTitle=医患沟通：细节出真知——解读LAP评估法中的有效沟通技巧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f0951259e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734654, encodeId=ae6d1e3465419, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=AACR 2015：女性患者福音！Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效, objectType=article, longId=49756, objectId=704249e564a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=704249e564a, replyNumber=0, likeNumber=89, createdTime=2015-06-20, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=704249e564a, moduleTitle=AACR 2015：女性患者福音！Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=704249e564a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734652, encodeId=b0761e34652c6, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=阿斯利康“死去”的抗癌药物Olaparib“复活”, objectType=article, longId=37141, objectId=ef013e1416c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef013e1416c, replyNumber=0, likeNumber=68, createdTime=2014-09-24, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef013e1416c, moduleTitle=阿斯利康“死去”的抗癌药物Olaparib“复活”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef013e1416c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734653, encodeId=1d041e34653bc, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=欧盟医药管理部门将表决是否加速阿斯利康卵巢癌药物olaparib审批流程, objectType=article, longId=41335, objectId=956741335b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=956741335b1, replyNumber=0, likeNumber=92, createdTime=2015-09-21, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=956741335b1, moduleTitle=欧盟医药管理部门将表决是否加速阿斯利康卵巢癌药物olaparib审批流程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=956741335b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734649, encodeId=8d131e34649a0, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=GSK与Galapagos的银屑病药物GSK2586184中期试验达终点, objectType=article, longId=33653, objectId=fa033365384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa033365384, replyNumber=0, likeNumber=56, createdTime=2015-01-06, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa033365384, moduleTitle=GSK与Galapagos的银屑病药物GSK2586184中期试验达终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa033365384)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734650, encodeId=6fb01e346508d, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=JAMA：evolocumab降LDL-C（LAPLACE-2 试验）, objectType=article, longId=34791, objectId=e77c34e9112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e77c34e9112, replyNumber=0, likeNumber=74, createdTime=2014-06-29, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e77c34e9112, moduleTitle=JAMA：evolocumab降LDL-C（LAPLACE-2 试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e77c34e9112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734651, encodeId=e6c81e346513d, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=阿斯利康抗癌药olaparib上市之路坎坷不平, objectType=article, longId=37015, objectId=47733e0152d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47733e0152d, replyNumber=0, likeNumber=107, createdTime=2015-03-18, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47733e0152d, moduleTitle=阿斯利康抗癌药olaparib上市之路坎坷不平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47733e0152d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734648, encodeId=a85e1e34648d4, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=Clin Cardiol：Evolucumab降低LDL-C（LAPLACE-2和RUTHERFORD-2试验）, objectType=article, longId=30220, objectId=a285302209d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a285302209d, replyNumber=0, likeNumber=69, createdTime=2014-11-03, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a285302209d, moduleTitle=Clin Cardiol：Evolucumab降低LDL-C（LAPLACE-2和RUTHERFORD-2试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a285302209d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734647, encodeId=211b1e3464730, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, objectTitle=阿斯利康启动olaparib III期SOLO项目, objectType=article, longId=24122, objectId=04fd241222d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04fd241222d, replyNumber=0, likeNumber=60, createdTime=2014-04-29, rootId=0, userName=LSJ122, userId=06de33803044, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04fd241222d, moduleTitle=阿斯利康启动olaparib III期SOLO项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04fd241222d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

LAP

2020-05-29

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

卵巢癌新药olaparib获3期临床突破

2017-05-01

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

Neurology：ELAPSS评分可以预测未破裂颅内动脉瘤生长风险吗？

2017-10-10

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

J Periodontol：非手术治疗可以有效减少LAP中Aa的JP2克隆表型

2018-01-06

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望

2017-10-15

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

J Endod：GuttaFlow Bioseal, GuttaFlow2, MTA Fillapex和AH Plus对人牙周膜干细胞的毒性研究

2017-06-12

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

Hepatology：DAA治疗失败的基因1 型丙型肝炎患者中，Sofosbuvir-velpatasvir-voxilaprevir使用效果评估

2018-01-06

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

【ASCO 2016】预告：奥拉帕利（Olaparib）和BRCA突变相关研究

2016-09-23

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

ASCO 2016：奥拉帕利（Olaparib）全面开战：卵巢癌、乳腺癌、胃癌

2016-10-02

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

lapatinib以及trastuzumab组合可以11天内消灭特定乳腺癌

2016-06-06

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

医患沟通：细节出真知——解读LAP评估法中的有效沟通技巧

2015-11-04

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

AACR 2015：女性患者福音！Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效

2015-06-20

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

阿斯利康“死去”的抗癌药物Olaparib“复活”

2014-09-24

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

欧盟医药管理部门将表决是否加速阿斯利康卵巢癌药物olaparib审批流程

2015-09-21

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

GSK与Galapagos的银屑病药物GSK2586184中期试验达终点

2015-01-06

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

JAMA：evolocumab降LDL-C（LAPLACE-2 试验）

2014-06-29

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

阿斯利康抗癌药olaparib上市之路坎坷不平

2015-03-18

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

Clin Cardiol：Evolucumab降低LDL-C（LAPLACE-2和RUTHERFORD-2试验）

2014-11-03

LSJ122 (审核中...)

前往app查看评论内容

#LAP#

阿斯利康启动olaparib III期SOLO项目

2014-04-29

科室
- - 订阅+
  - 更多科室
工具
服务